On April 9, 2026 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) reported that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place on April 17-22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate ("ATTC") will be presented. The payload of HMPL-A580 potently inhibited PI3K and PIKK family kinases, with IC50 ranging around 1 to 10 nM. Eurofins profiling across 418 kinases revealed the payload has excellent selectivity. By conjugating this potent payload with an anti-EGFR antibody via a cleavable linker, the ATTC compound HMPL-A580 demonstrated robust anti-tumor effect. Upon binding to EGFR-expression cancer cell line, HMPL-A580 underwent rapid internalization, lysosomal trafficking, payload release, and PAM and PIKK signaling inhibition to induce tumor cell apoptosis. In a 38-human solid tumor cell line panel, HMPL-A580 potently inhibited EGFR-expression tumor cell proliferation. The tumor cells harboring EGFR high expression, EGFR mut or PAM alterations were more sensitive to HMPL-A580. HMPL-A580 showed a strong bystander effect when EGFR-negative cells co-cultured with EGFR-expression cells. In human tumor xenograft models in mice, HMPL-A580, administered intravenously at 1~10 mg/kg once weekly for two weeks, demonstrated a dose / exposure-dependent anti-tumor activity in multiple EGFR-expression models, which is associated with much stronger target inhibition and suppression of downstream functions than antibody and payload alone treatment. The preliminary results demonstrated that HMPL-A580 was stable in human, monkey, rat and mouse plasma, and showed favorable PK property in cynomolgus monkeys.

Updated results from a multicenter, single-arm Phase Ib/II trial of surufatinib plus sintilimab and capecitabine in previously treated metastatic small bowel adenocarcinoma and appendiceal carcinoma, as well as results from a exploratory Phase II study of surufatinib combined with gemcitabine and nab-paclitaxel ("AG") for the treatment of locally advanced or metastatic pancreatic ductal adenocarcinoma patients following AG induction therapy will also be presented.

Details of the presentations are as follows:

Abstract title

Presenter / Lead author

Presentation details

SPONSORED STUDIES

Discovery of HMPL-A580, a first-in-class antibody-targeted therapy conjugate (ATTC) of a novel PI3K/PIKK inhibitor payload linked to an anti-EGFR antibody

Yu Cai, HUTCHMED, Shanghai, China

4549

Poster Session (PO.ET01.03)

Tuesday, April 21, 2026

INVESTIGATOR-INITIATED STUDIES

Updated multicenter phase Ib/II analysis of surufatinib plus sintilimab and capecitabine in previously treated metastatic small bowel adenocarcinoma and appendiceal carcinoma

Xiaoyu Xie, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

CT160

Poster Session (PO.CT01.05)

Monday, April 20, 2026

Sequential treatment with surufatinib combined with gemcitabine and nab-paclitaxel (AG) or AG alone as first-line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC) after 6 weeks of AG induction therapy: A two-cohort, exploratory phase II study

Jin Xu, Fudan University Shanghai Cancer Center, Shanghai, China

CT146

Poster Session (PO.CT01.05)

Monday, April 20, 2026

About the ATTC Platform and HMPL-A580

HUTCHMED’s ATTC platform represents a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payloads to deliver dual mechanisms of action. Unlike traditional cytotoxin-based Antibody Drug Conjugates, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in efficacy and safety.

The first family of ATTCs are based on a novel payload that targets the PI3K/AKT/mTOR ("PAM") pathway, a critical intracellular network involved in cell growth, survival, and division. Alterations in the PAM pathway are frequently associated with poor prognosis and resistance to treatment across various cancers. However, existing PAM-targeted drugs face significant challenges, including on-target toxicities that restrict dosing, feedback loops that enable pathway reactivation, and insufficient tumor-specific delivery. Preclinical data from the first ATTC candidate based on this potent novel PI3K/PIKK inhibitor payload, HMPL-A251, was presented at AACR (Free AACR Whitepaper)-NCI-EORTC in October 2025.

HMPL-A580 is the second ATTC candidate based on this novel payload. It is a first-in-class ATTC comprising a highly selective and potent PI3K/PIKK small-molecule inhibitor payload linked to an anti-EGFR antibody via a cleavable linker. EGFR is highly expressed in multiple types of solid tumors and is well recognized as a driving force in tumorigenesis and disease progression. By conjugating this highly novel PI3K/PIKK payload to an anti-EGFR antibody, HMPL-A580 is designed to deliver targeted pathway inhibition directly into EGFR-expressing tumor cells, thereby potentially overcoming the systemic toxicity and narrow therapeutic index historically associated with PI3K/PIKK inhibitors. This approach aims to achieve deeper and more durable target inhibition while improving the overall tolerability profile.

HUTCHMED has demonstrated how its partnerships leverage the expertise of multinational pharmaceutical companies to accelerate bringing novel medicines to address large unmet needs around the world, and plans to apply this strategy to its ATTC technology this year.

About Surufatinib

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA. HUTCHMED currently retains all rights to surufatinib worldwide.

(Press release, Hutchison China MediTech, APR 9, 2026, View Source [SID1234664267])

On April 9, 2026 BostonGene, a developer of the leading AI foundation model for tumor and immune biology, reported that 13 abstracts have been selected for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, held from April 17 – 22, at the San Diego Convention Center in San Diego, CA. BostonGene will be exhibiting at booth #4613.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BostonGene will demonstrate how its leading AI foundation model for tumor and immune biology is redefining the drug development lifecycle by providing biopharma partners with a biologically grounded roadmap from early discovery through late-stage clinical trials. Integrating genomic, transcriptomic, and spatial insights, BostonGene’s presentations highlight a sophisticated suite of AI-driven capabilities designed to accelerate and de-risk the pharmaceutical pipeline. Key research includes the use of ReadyScore and Lymphly for precision patient stratification and target identification, RNA-aware diffusion models to predict drug-induced tissue dynamics, and AI-based image batch correction to ensure trial data integrity by focusing on true biologic signals. Furthermore, in collaboration with leading institutions, BostonGene will showcase how longitudinal multiomic profiling identifies actionable biomarkers and resistance pathways often missed by traditional methods.

Details of BostonGene’s presentations at AACR (Free AACR Whitepaper) are below:

Oral presentation
Session: CT012
Title: A phase 2 single-arm open-label trial evaluating zanidatamab in patients with early-stage HER2-positive breast cancer: The NeoZanHER study
Date & time: April 18 | 12:50 PM – 1:00 PM
Presenter: Funda Meric-Bernstam, MD, UT MD Anderson

BostonGene’s integrated whole exome sequencing (WES) and RNA-seq platform was applied to uncover markers of response to HER2-targeting zanidatamab in a small cohort of patients with early-stage HER2-positive breast cancer. Early findings revealed high efficacy and manageable safety profile in select patients, underscoring the feasibility of de-escalating to HER2-targeted therapy alone for this cancer.

Research done in collaboration with UT MD Anderson

Poster presentations
Poster: 114
Title: Unraveling tumor- and tissue-specific gene expression patterns from plasma-derived cfRNA
Date & time: Sunday, April 19 | 2:00 PM – 5:00 PM
Presenter: Desiree Schenk, BostonGene

BostonGene explored the utility of minimally invasive plasma-derived cell-free RNA (cfRNA) profiling for deconvolving tumor- and tissue-specific signals from a single blood draw. We uncovered tumor- and tissue-specific expression patterns in cfRNA that correlated with donor health or cancer status. Our findings support cfRNA signatures as a clinically relevant resource for optimizing patient stratification, trial design, discovery of novel drug targets and plasma-based biomarkers, and disease and treatment response monitoring.

Poster: 0452
Title: Therapeutic potential of AURKA inhibition in ER+ inflammatory breast cancer
Date & time: April 19 | 2:00 PM – 5:00 PM
Presenter: Surbhi Shivhare, PhD, UT MD Anderson

Applying BostonGene’s Tumor PortraitTM to analyze samples from ER+ inflammatory breast cancer (IBC) tumors, researchers at MD Anderson discovered amplified AURKA expression and an inverse relationship between AURKA and SMARCA4 expression. These findings suggest SMARCA4 as a putative synthetic lethality partner of AURKA, where therapeutic targeting of both could lead to cell death. BostonGene’s Tumor PortraitTM integrated genomic and transcriptomic data with clinical data to generate biologically grounded, actionable insights.

Research done in collaboration with UT MD Anderson

Poster: 2437
Title: A comparative scoring framework for BCMA-, GPRC5D- and CD38-targeted therapies in multiple myeloma
Date & time: Monday, April 20 | 9:00 AM – 12:00 PM
Presenter: Konstantin Chernyshov, PhD, BostonGene

BostonGene leveraged ReadyScore, a proprietary, next-generation sequencing-based scoring framework for BCMA-, GPRC5D-, and CD38-targeted therapies in multiple myeloma. This molecular stratification tool integrates tumor and microenvironment features to provide a comprehensive readiness profile to predict CAR-T response, T-cell engagers and monoclonal antibodies. By highlighting target readiness and treatment resistance pathways, the framework enables more precise biomarker-driven patient selection, informs therapeutic prioritization, and offers potential utility for optimizing trial design and translational decision-making.

Poster: 1451
Title: Visualizing the genotype–phenotype link: Predicting drug-induced tissue dynamics with RNA-based diffusion models
Date & time: Monday, April 20 | 9:00 AM – 12:00 PM
Presenter: Alexander Bagaev, PhD, BostonGene

BostonGene presents an RNA-aware diffusion model that predicts tissue morphology from gene expression to better understand genotype–phenotype relationships in cancer. The model integrates RNA embeddings from over 20,000 genes with histological image generation, trained on extensive paired RNA and H&E datasets. It produced realistic tissue images and successfully simulated drug-induced gene expression changes, capturing biologically meaningful tissue dynamics such as tertiary lymphoid structures and B-cell signatures. The approach helps predict how drugs affect tissue architecture, improving drug candidate selection, guiding early trial design, and reducing risks in drug development.

Poster: 3877
Title: Integrative application of Lymphly reveals shared molecular landscape across B-cell lymphomas
Date & time: Monday, April 20 | 2:00 PM – 5:00 PM
Presenter: Konstantin Chernyshov, PhD, BostonGene

BostonGene applied Lymphly, a unique, stable genetic classification framework for diffuse large B-cell lymphoma (DLBCL). When applied to ~3,500 samples, it uncovered previously unrecognized molecular relationships between DLBCL subtypes and other B-cell lymphomas. The analysis identified distinct subtype–disease links and shared genetic patterns, improving understanding of how lymphomas may transform into DLBCL and highlighting potential therapeutic targets across the B-cell lymphoma landscape.

Poster: 1468
Title: Germline whole exome sequencing implicates homologous recombination repair pathway genes as risk factors in SMARCB1 deficient renal medullary phenotypes without sickle hemoglobinopathies
Date & time: April 20 | 9:00 AM – 12:00 PM
Presenter: Pankaj Kumar Chauhan, PhD, UT MD Anderson

BostonGene’s genomic analysis explored two rare and aggressive kidney cancers: renal medullary carcinoma (RMC) and renal cell carcinoma with medullary phenotype (RCCU-MP). The study found that while both cancers showed similar immune-rich tumor environments, distinct genomic alterations were present in RCCU-MP that were absent in RMC. These results point to new genetic risk factors in RCCU-MP and support broader germline testing for patients with RCCU-MP.

Research done in collaboration with UT MD Anderson

Poster: 3763
Title: CCR7 expression and spatial distribution in inflammatory breast cancer: A baseline characterization for therapeutic targeting
Date & time: April 20 | 2:00 PM – 5:00 PM
Presenter: Surbhi Shivhare, PhD, UT MD Anderson

In collaboration with The University of Texas MD Anderson Cancer Center, BostonGene applied its multimodal molecular profiling platform to advance target discovery in inflammatory breast cancer. By integrating genomic, transcriptomic, and spatial data, BostonGene uncovered key biological features of CCR7 that support its therapeutic relevance. This work highlights BostonGene’s ability to generate clinically actionable insights to prioritize targets, refine patient selection strategies, and accelerate oncology drug development.

Research done in collaboration with UT MD Anderson

Poster: 5251
Title: Precise description of metabolomic states using NGS uncover new potential biomarkers of response to TKIs in ccRCC
Date & time: Tuesday, April 21 | 9:00 AM – 12:00 PM
Presenter: Nikita Kotlov, PhD, BostonGene

BostonGene developed specific metabolic gene signatures to inform prediction of tyrosine kinase inhibitor (TKI) response in patients with clear cell renal cell carcinoma (ccRCC). Our refined metabolic signatures uniquely integrate transcriptomic and metabolic data to reveal strong associations with TKI response, overall survival and tumor microenvironment subtypes, representing potent candidate biomarkers for early-phase clinical trial design and patient stratification aimed at overcoming TKI resistance.

Poster: 4164
Title: Implementation of a diffusion-based color checker for histological image batch correction
Date & time: Tuesday, April 21 | 9:00 AM – 12:00 PM
Presenter: Alexander Bagaev, PhD, BostonGene

BostonGene will present a novel AI-powered tool to enhance histological image analysis through batch correction. Leveraging stable diffusion models, the tool standardizes whole slide images collected on different scanners by mitigating technical variations and artifacts. The diffusion-based framework optimizes AI-driven image analysis workflows, offering a scalable solution for harmonizing large multi-site histological datasets.

Poster: 5421
Title: Determining the benefit of comprehensive molecular testing in advanced cancers: BostonGene and Exigent Genomic INsight (BEGIN) study
Date & time: Tuesday, April 21 | 9:00 AM – 12:00 PM
Presenter: Sibel Blau, MD, Northwest Medical Specialties

The BEGIN study, a collaboration between BostonGene and the Exigent Research Network, evaluated integrated DNA/RNA genomic profiling in community oncology practices. Among patients with advanced cancers, 93% had actionable findings, with many identified through RNA sequencing only. Comprehensive results influenced treatment decisions, including matching patients to standard of care and ongoing trial options, highlighting the patient-level impact of combined DNA/RNA testing in expanding precision oncology options in community settings.

Research done in collaboration with Exigent Research Network Investigators

Poster: CT277
Title: IvoLoC trial: A phase II trial evaluating the efficacy of ivonescimab in metastatic endocrine refractory HR-positive HER2-negative or triple negative invasive lobular carcinoma (ILC)
Date & time: Tuesday, April 21 | 2:00 PM – 5:00 PM
Presenter: Jason Mouabbi, MD, UT MD Anderson

In an ongoing clinical trial with MD Anderson Cancer Center, BostonGene performed multimodal longitudinal blood and tissue analysis of metastatic invasive lobular carcinoma patients receiving the bispecific antibody targeting PD-1 and VEGF, ivonescimab. Beyond efficacy and durability, this study evaluated the molecular correlates linking clinical outcomes with tumor microenvironment subtypes while assessing circulating tumor DNA dynamics, biomarkers of response and resistance, and predictive responder scores.

Research done in collaboration with UT MD Anderson

Poster: 7935
Title: Multimodal immunotherapy remodels the tumor microenvironment in hepatocellular carcinoma: Integrative spatial and transcriptomic profiling from a Phase II trial
Date & time: April 22 | 9:00 AM – 12:00 PM
Presenter: Lionel Aurelien Kankeu Fonkoua, MD, Mayo Clinic Cancer Center

BostonGene’s spatial and transcriptomic analysis was used in a Phase II trial to show that combining radiotherapy, dendritic cell vaccination, PD-L1 blockade, and VEGF inhibition could reshape the tumor environment in hepatocellular carcinoma (HCC). This multimodal approach helped turn immune-resistant "cold" tumors into immune-active states, improving T-cell responses and vascular health. The findings highlight promising strategies to overcome treatment resistance in HCC and reinforce BostonGene’s role in advancing precision immunotherapy.

Research done in collaboration with Mayo Clinic

The abstracts will be published in an online-only Proceedings supplement to the AACR (Free AACR Whitepaper) journal Cancer Research.

(Press release, BostonGene, APR 9, 2026, View Source [SID1234664283])

On April 9, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead’s oncology pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To date, Gilead has leveraged Tempus’ extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy, health outcomes analysis and clinical real world evidence. The expanded agreement provides Gilead with enterprise-wide access to Tempus’ AI-driven Lens platform, unlocking access to broader datasets across multiple indications and integrating dedicated Tempus analytical services.

"We are excited to announce this expanded partnership with Tempus that reflects our shared priority of putting patients at the heart of innovation," said Patrick Loerch, SVP of Clinical Data Science at Gilead Sciences. "By combining Gilead’s scientific expertise with Tempus’ real world data insights in oncology, we aim to maximize generation of key insights to help inform clinical decision making and ultimately improve care for cancer patients."

"By providing access to the Tempus multimodal data library, we are empowering the Gilead team to further fuel its R&D engine with AI-driven insights," said Ryan Fukushima, CEO of Tempus Data & Apps. "We are thrilled to expand this collaboration, offering the multimodal depth necessary to uncover critical biological insights. This approach helps navigate billions of data points to find the ‘signal in the noise,’ ultimately increasing the probability of success for life-altering medicines."

(Press release, Tempus, APR 9, 2026, View Source [SID1234664284])

On April 9, 2026 Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, reported that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

(Press release, Immix Biopharma, APR 9, 2026, View Source [SID1234664269])

On April 9, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") reported that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company’s resubmitted New Drug Application (NDA) for TLX101-Px1, (Pixclara2, Floretyrosine F 18 or 18F-FET), an investigational PET3 agent for the imaging of glioma (brain cancer), and has assigned a PDUFA4 goal date of September 11, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The approval of TLX101-Px will fulfil a significant unmet medical need for the characterization of recurrent or progressive glioma from treatment related changes in both adult and pediatric patients5. Neuroimaging of glioma with 18F-FET is already broadly recommended in international clinical practice guidelines – including NCCN Guidelines6 – and TLX101-Px has been granted Orphan Drug7 and Fast Track8 designations by the FDA.

"There remains a critical unmet need in improving our ability to image residual glioma after treatment," said Thomas Hope, MD, Vice Chair, Department of Radiology and Biomedical Imaging, University of California, San Francisco (UCSF). "We have worked with Telix for the last three years to help leverage our clinical data to help make FET-PET9 available to patients in the United States."

Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added, "Distinguishing tumor progression from treatment-related change remains one of the most challenging aspects of glioma care. PET imaging with 18F-FET is an important tool in clinical practice worldwide, and the FDA’s acceptance of this application is a meaningful step toward broader access for patients and clinicians in the United States."

Kevin Richardson, CEO, Telix Precision Medicine, added, "The FDA’s acceptance of our NDA resubmission is an important milestone for Telix. We appreciate the FDA’s constructive engagement and look forward to working closely with the Agency to urgently obtain approval and then bring this product to market for the benefit of patients."

Telix’s FY 2026 financial guidance does not include any revenue contribution from TLX101-Px.

About TLX101-Px

TLX101-Px is a PET imaging candidate, which has been granted Fast Track and Orphan Drug designations by the FDA for the characterization of recurrent or progressive glioma from treatment related changes. TLX101-Px targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). This enables TLX101-Px to be potentially utilized as a patient selection and response assessment tool for Telix’s LAT1-targeting therapy candidate TLX101-Tx (iodofalan 131I), currently under investigation in the pivotal IPAX-BrIGHT trial in patients with recurrent glioblastoma10. TLX101-Px and TLX101-Tx have not received marketing authorizations in any jurisdiction.

About gliomas

Gliomas are diffusely infiltrative tumors that affect the surrounding brain tissue. They are the most common form of central nervous system (CNS) cancer that originates from glial cells, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors11. In the U.S., there are approximately 24,000 new glioma cases diagnosed annually12. Glioblastoma (GBM) is a high-grade glioma and the most common and aggressive form of primary brain cancer. The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients13, with an expected survival duration of 12-15 months from diagnosis.

(Press release, Telix Pharmaceuticals, APR 9, 2026, View Source [SID1234664285])